GI
ENTA icon

GAMMA Investing’s Enanta Pharmaceuticals ENTA Stock Holding History

GAMMA Investing’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8K Sell
1,355
-46
-3% -$618 ﹤0.01% 2840
2026
Q1 		$17.7K Buy
1,401
+70
+5% +$938 ﹤0.01% 2774
2025
Q4 		$21K Hold
1,331
– – ﹤0.01% 2583
2025
Q3 		$15.9K Buy
1,331
+771
+138% +$6.16K ﹤0.01% 2641
2025
Q2 		$4.23K Sell
560
-762
-58% -$4.58K ﹤0.01% 3185
2025
Q1 		$7.3K Buy
+1,322
New +$8.17K ﹤0.01% 2897
2024
Q4 		– Sell
-29
Closed -$300 – 3793
2024
Q3 		$300 Sell
29
-14
-33% -$183 ﹤0.01% 3455
2024
Q2 		$558 Hold
43
– – ﹤0.01% 3193
2024
Q1 		$751 Hold
43
– – ﹤0.01% 3007
2023
Q4 		$522 Buy
+43
New +$401 ﹤0.01% 2958

Other funds holding ENTA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

GAMMA Investing's ENTA Position: Q2 2026 in Review

GAMMA Investing reduced its Enanta Pharmaceuticals (ENTA) stake by 3.3% in Q2 2026, selling an estimated $618 and leaving 1,355 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

GAMMA Investing first reported a position in ENTA in Q4 2023 and has held it in 10 quarters since. The position peaked at $21K in Q4 2025. 6 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • GAMMA Investing held 1,355 shares of Enanta Pharmaceuticals worth $19.8K as of Q2 2026.
  • GAMMA Investing sold 46 Enanta Pharmaceuticals shares in Q2 2026, an estimated $618.
  • Enanta Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2840 holding.
  • GAMMA Investing first reported a position in Enanta Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • GAMMA Investing's Enanta Pharmaceuticals position peaked at $21K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.